Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%

Executive Summary

Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.

You may also be interested in...



Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems

Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.

Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.

Schering Desloratadine Launch Ads In U.K. Include Decongestant Claim

Schering-Plough's launch campaign for desloratadine in the U.K. includes a claim that the antihistamine has decongestant properties.

UsernamePublicRestriction

Register

PS037414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel